India’s BRICS health agenda is increasingly moving beyond traditional public-health cooperation. As the country hosts the bloc’s Health Ministers’ Meeting in Chandigarh from July 22 to 24, 2026, digital health, artificial intelligence, medicines and health innovation are receiving greater attention.
For Indian businesses, the question is whether this cooperation can eventually create more opportunities for pharmaceutical companies, health-tech firms and AI developers.
The answer is potentially yes, but BRICS does not function as a single healthcare market. Turning policy discussions into commercial gains will require regulatory cooperation, research partnerships and actual market access.
India BRICS Health Meeting
India already has a substantial pharmaceutical export business. World Bank WITS data, based on UN Comtrade, puts India’s pharmaceutical exports at about $25.89 billion in 2025. South Africa accounted for roughly $676.2 million, while Brazil received around $596.5 million of India’s pharmaceutical exports.
These numbers show that BRICS markets are already part of India’s pharmaceutical trade story. The potential opportunity is whether deeper cooperation can help Indian companies expand their presence across these markets over time.
The 2025 BRICS Health Ministers’ Declaration called for stronger local and regional production of medicines, vaccines, diagnostics and other health products. It also highlighted the importance of resilient and diversified supply chains. Such priorities align with India’s established pharmaceutical manufacturing base, although the declaration itself does not guarantee easier market access for Indian companies.
A recent example shows the commercial potential of individual BRICS markets. Reuters reported in July that Sun Pharma received South African approval for its generic semaglutide product, making South Africa its second cleared market after India.
The development followed the expiry of Novo Nordisk’s semaglutide patent in South Africa, showing that regulatory and intellectual-property changes can be more important to market entry than BRICS membership alone.
Digital Health Takes Centre Stage
The digital-health opportunity is more emerging than immediate.
On July 24, India will host a BRICS dialogue titled “From Digital Health Records to AI-Enabled Healthcare.” The discussion is expected to focus on interoperable data infrastructure and responsible artificial intelligence in healthcare.
For Indian technology companies, the significance lies in the possibility of greater cooperation around digital health systems. If countries eventually align standards or collaborate on technology, it could create opportunities for companies working in health software, data systems and digital healthcare services.
But significant barriers remain. BRICS countries have different healthcare systems, data rules, regulatory frameworks and procurement processes. Discussions on interoperability therefore represent a possible starting point, not evidence that Indian health-tech firms will automatically gain access to new markets.
AI Opens New Possibilities
AI is also becoming part of the wider BRICS science and technology agenda.
The 2026 BRICS Science, Technology and Innovation Framework Programme identifies health, biotechnology and biomedicine as priority areas. Its focus includes genomics, AI-assisted discovery, personalised medicine, diagnostics, digital health, telemedicine and AI-enabled healthcare systems.
This creates a potential foundation for research collaboration in areas such as drug discovery and diagnostics. For Indian companies and institutions, partnerships with counterparts in other BRICS countries could eventually support innovation and technology development.
However, this should not be mistaken for an immediate commercial opportunity. The framework is primarily designed around collaborative research, while healthcare AI products still face questions around clinical safety, data protection and country-specific regulation.
The Market Access Test
The biggest question is what happens after the declarations and meetings.
A BRICS agreement supporting affordable medicines does not automatically remove regulatory barriers. Likewise, discussions around digital health do not create a common healthcare market overnight.
For Indian companies, the opportunity becomes more meaningful if cooperation eventually leads to joint research, regulatory alignment, technology pilots or procurement partnerships.
That makes the BRICS health push worth watching from a business perspective. India already has a significant pharmaceutical export base, while digital health and AI are emerging areas of international cooperation. But the real test will be whether policy discussions translate into practical mechanisms that make it easier for companies to operate across borders.
For now, BRICS is best viewed not as a ready-made new market for Indian healthcare companies, but as a platform that could, over time, help create the conditions for new business opportunities.
